EQUITY.GURU podcast - Investing for millennials and madmen
Aequus Pharmaceuticals (AQS.V) CEO, Doug Janzen - EG Interview Highlights

Aequus Pharmaceuticals (AQS.V) CEO, Doug Janzen - EG Interview Highlights

November 23, 2020

Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval.

Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors.

Here are the highlights!

Aequus Pharmaceuticals (AQS.V) CEO, Doug Janzen - EG Interview Part 2

Aequus Pharmaceuticals (AQS.V) CEO, Doug Janzen - EG Interview Part 2

November 23, 2020

Welcome to the second installment!

Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval.

Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Listen in!

Aequus Pharmaceuticals (AQS.V) CEO, Doug Janzen - EG Interview Part 1

Aequus Pharmaceuticals (AQS.V) CEO, Doug Janzen - EG Interview Part 1

November 23, 2020

Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval.

Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Tune in!

Sixth Wave Innovations (SIXW.C) Equity Guru Zoom Interview Part 2

Sixth Wave Innovations (SIXW.C) Equity Guru Zoom Interview Part 2

November 14, 2020

Time for part 2! Sixth Wave Innovations (SIXW.C), a world leader in molecular detection and extraction, is working to disrupt the market for Covid rapid testing as well as mineral extraction for gold mining and last but not least, cannabis extraction. Equity Guru's own Chris Parry spoke with company president, CEO and founder, Jonathan Gluckman, PhD., to get an inside look at the company and what potential it holds for investors. Tune in!

Sixth Wave Innovations (SIXW.C) Equity Guru Zoom Interview Part 1

Sixth Wave Innovations (SIXW.C) Equity Guru Zoom Interview Part 1

November 14, 2020

Sixth Wave Innovations (SIXW.C), a world leader in molecular detection and extraction, is working to disrupt the market for Covid rapid testing as well as mineral extraction for gold mining and last but not least, cannabis extraction. Equity Guru's own Chris Parry spoke with company president, CEO and founder, Jonathan Gluckman, PhD., to get an inside look at the company and what potential it holds for investors. Tune in!

Pure Extracts Technologies (PULL.C) CEO explains extraction potential in multiple markets (Part 2)

Pure Extracts Technologies (PULL.C) CEO explains extraction potential in multiple markets (Part 2)

November 13, 2020

This is the final segment where Pure Extracts Technologies (PULL.C) CEO, Ben Nikolaevsky, speaks with Equity Guru's own, Chris Parry, to outline the companies cross market potential in plant-based extraction. Tune in!

Pure Extracts Technologies (PULL.C) CEO explains extraction potential in multiple markets (Part 1)

Pure Extracts Technologies (PULL.C) CEO explains extraction potential in multiple markets (Part 1)

November 13, 2020

It's not all about legal cannabis anymore, Pure Extracts Technologies (PULL.C) CEO, Ben Nikolaevsky, speaks with Equity Guru's own, Chris Parry, to outline the companies cross market potential in plant-based extraction. Tune in!

KWESST Micro Systems Inc - Zoom Interview with David Luxton Pt.3

KWESST Micro Systems Inc - Zoom Interview with David Luxton Pt.3

October 28, 2020

Ahead of Kwesst's initial public offering (IPO), Equity Guru's own Chris Parry talks with the company's Executive Chairman David E. Luxton to gives us a closer look into what the company does and where they're headed.

KWESST podcast pt.2 – Executive Chairman David Luxton talks about laser warfare

KWESST podcast pt.2 – Executive Chairman David Luxton talks about laser warfare

June 19, 2020

KWESST is a Canadian military tech company that is “making dumb weapons smart” by developing proprietary technology for the military and homeland security markets.

The total Global Defense Budget is estimated at USD $1.8 Trillion in 2020 and the market is expected to grow to USD $2.3 Trillion by 2028.

“Thirteen conflicts are identified as top priorities for the United States,” states The Council on Foreign relations.

KWESST has a diversified product line, based on a single core technology, called Micro Integrated Sensor Systems Technology (MISST), which involves miniaturized sensors, optics, ballistics and software which claims to significantly jack-up mission capability.

In this pt. 2 podcast, Equity Guru’s Guy Bennett talks to David Luxton, Executive Chairman of KWESST about laser warfare, shot counters, the management team, global markets, 2020 objectives, share structure and KWESST’s “Blue Sky Story”.

Full Disclosure:  KWESST is an Equity Guru marketing client.

Business, A.I. and the future of tech: a conversation with PredictMedix’s (PMED.V) Kapil Raval

Business, A.I. and the future of tech: a conversation with PredictMedix’s (PMED.V) Kapil Raval

June 18, 2020

Small caps in Canada, especially in tech, are full of faux-companies. You know,
the kind where the problem being solved isn’t really a problem, and the
“technology” being advertised is actually five years old.

PredictMedix (PMED.C) isn’t one of them.

The last time I wrote about PredictMedix, I made an argument about:

  1. The resilience of pharmaceuticals as a sector, and
  2. The scalability of the tech, and hence the business

Since then, the stock has been pumped. Listen in as Arth talks with Kapil Raval!

Play this podcast on Podbean App